Manufacturing Strengths

  • Facility strictly adheres to environment, health and safety program (EHS) and is approved by WHO.
  • It is high-tech, state of the art facility as per cGMP standards.
  • Naprod is a well known name is the global pharmaceutical industry as a manufacturer of quality products in the niche segments like oncology and anesthesia.

Manufacturing Portfolio

  • General injection Facility
    • Liquid and Lyophilized Injection
  • Oncology Injection Facility
    • Liquid and Lyophilized Injection
    • Solid Oral dosage (Tablets/ Capsules)

Product Range

  • Oncology
  • Cardiovasculars
  • Anaesthetics
  • Anti-Ulceratives
  • Anti-Infectives
Cephalosporins , Critical Care Range, Anesthesia and Veterinary
range manufactured by “Samrudh Pharma” in collaboration with Naprod Team.

Research & Development focus

  • To develop injectable lyophilized technology and bio-equivalent generics meeting global regulatory requirements.
  • Process improvement of contract manufactured molecules.
  • Process optimization and improvement.
  • Research related to in-house production of APIs & Formulations.
  • To provide “incremental innovations” for existing products i.e. to explore new indications, to develop innovative, therapeutically beneficial formulations to extend the product life and the market segment.
Significant success in the following thrust areas:
  • Formulation development (focus on antineoplastics and critical care range going off patent upto 2024)
  • Intellectual property management
  • Analytical development
Naprod Product Range
KNOW MORE
Samrudh Product Range
KNOW MORE
Quality Policy

Naprod’s core purpose and commitment is to consistently deliver safe and effective products to patients; a mission that everyone in Naprod believes passionately.
We at Naprod, maintain a quality-focused approach to ensure that top priority is placed on the safety, efficacy and reliability of our products. The safety of our patients and consumers, the quality of data supporting regulatory submissions and communication with our business partners/stakeholders.

Naprod leadership has appropriate systems and processes in place to ensure the consistency of quality of drug products.
Every single employee is committed to maintaining a quality culture with high compliance and processes to ensure product quality and patient safety meeting the established requirement of our customers/regulatory requirements and business.

We effectively involve all our employees and vendors in our endeavour to exceed customer expectations, to prevent defects and continually improve our processes to add value to the businesses we work with.

Formulation & Development

In line with our philosophy of knowledge-led growth, we have invested in a state-of-the-art F & D facility. Our research team has highly qualified scientists with doctoral experience from leading universities/institutions and is engaged in drug delivery systems, process development, analytical research and has cross functional lead.

Formulation development is a key area of product development that can determine patentability, life cycle and ultimately, the success of a pharmaceutical product. Formulation Development integrates functions and personnel into their product development cycle in many different ways, from early development lab scale to scale up to production scale technology transfer at site and off-site.

Formulation Development is a completely dedicated department for the development of a pharmaceutical product for the worldwide markets considering the patent and development strategy. Formulation Development also includes but is not limited to development of a stable and Bio-Equivalent Formulation and Transfer of the developed technology to the manufacturing site including dossier compilation and regulatory submission and addressing to any query from the regulatory agency to get the dossier approved in the coordination of cross-functional team (CFT).

Our R&D primarily focuses on

  • Development of injectable lyophilized technology and bioequivalent generics meeting global regulatory requirements.
  • Process improvement of contract manufactured molecules.
  • Process optimization and improvement.
  • Research related to the in-house production of formulations, etc.
  • Providing ‘incremental innovation’ for existing products i.e. to look for new indications, to develop innovative, therapeutically beneficial formulations to extend the product life and the market segment.

We have achieved significant success in the following thrust areas:

  • Formulation development.

Our pharmaceutical products research team offer a portfolio of differentiated drugs and we have the ability to handle multiple dosage forms such as:

  • Solid dosage pharmaceutical products (capsules, tablets)
  • Injectables (sterile solutions and anticancer injectables);
  • Lyophilized pharmaceutical products (including lyophilized cytotoxic injectables);

Our injectable portfolio includes Oncology injectables, Anesthetics, Steroids, and on development level Emulsions, Micro-emulsion, Suspensions.

With a portfolio of more than 500 products for various markets, the development team has vertically integrated operations for greater control: patent navigation, process development, scaling-up, tech-transfer, manufacturing finished formulations, registrations and supply chain management.

Naprod’s development arm has dedicated teams of highly qualified scientists working on development and registration of generic as well as branded products.

Production Capacity

  • Injectable : Oncology
    • Lyophilized Powder for injection - 3.5Million/Year
    • Liquid Injectables - 3 Millions/ Year
  • Solid Oral Dosage : Oncology
    • Tablets (Coated / Uncoated) – 30 Millions/ Year
    • Hard Gelatin Capsules – 15 Millions / Year
  • Injectable : General
    • Lyophilized Powder for injection – 10.0 Millions / Year
    • Liquid Injectable – 1.0 Millions / Year